|
|
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
普维替尼在HER2表达阳性晚期实体瘤患者中的耐受性及药代动力学研究
[Translation] Tolerability and pharmacokinetics of pavitinib in patients with HER2-positive advanced solid tumors
评价HER2表达阳性晚期实体瘤患者单次及后续多次口服普维替尼胶囊的安全性、耐受性和药代动力学特征,为后期临床试验的方案设计提供依据
[Translation] To evaluate the safety, tolerability and pharmacokinetic characteristics of single and subsequent multiple oral administrations of pavitinib capsules in patients with HER2-positive advanced solid tumors, and to provide basis for the design of late-stage clinical trials
100 Clinical Results associated with Hangzhou Derun Yucheng Biological Technology Co Ltd
0 Patents (Medical) associated with Hangzhou Derun Yucheng Biological Technology Co Ltd
100 Deals associated with Hangzhou Derun Yucheng Biological Technology Co Ltd
100 Translational Medicine associated with Hangzhou Derun Yucheng Biological Technology Co Ltd